Second-line tyrosine kinase inhibitors (TKIs) versus immunotherapy (IO) for advanced hepatocellular carcinoma (HCC): Real-world efficacy and safety analysis in patients with varying liver dysfunction.
Jeffrey Xia(Stanford University), Sukeshi Patel Arora(The University of Texas MD Anderson Cancer Center), Jonathan Gelfond(The University of Texas at San Antonio Health Science Center)
Cited by 0
Related Papers
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability
|EBioMedicine|2023|275
Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer
|European Urology|2018|224
Strain-Dependent Variation in 18S Ribosomal DNA Copy Numbers in <i>Aspergillus fumigatus</i>
|Journal of Clinical Microbiology|2009|197
A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects
|Experimental Gerontology|2018|168
Acarbose improves health and lifespan in aging HET3 mice
|Aging Cell|2019|145